Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
J Antimicrob Chemother
; 61(6): 1328-31, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18353805
ABSTRACT
OBJECTIVES:
To evaluate the ability of moxifloxacin to penetrate healthy brain barriers.METHODS:
Fifty patients received a single oral dose of 400 mg as an antimicrobial prophylaxis regimen for a short urological procedure under spinal anaesthesia. Serum and cerebrospinal fluid (CSF) were sampled at different time intervals post-drug intake and patients were divided into five groups, as follows group I 0.5-1 h; group II 1-2 h; group III 2-4 h; group IV 4-6 h; and group V 6-8 h. Concentrations of moxifloxacin were estimated after analysis by an HPLC system. Bactericidal activity of CSF samples of groups III and IV was assessed by a microdilution technique against two penicillin-resistant isolates of Streptococcus pneumoniae with MICs of moxifloxacin of 0.19 and 0.125 mg/L, respectively.RESULTS:
Mean CSF concentrations of moxifloxacin of groups I, II, III, IV and V were 0.19, 0.87, 3.00, 4.07 and 1.82 mg/L, respectively. The mean bactericidal activity of CSF of group III was 8 and that of group IV was 4.CONCLUSIONS:
Single oral intake of 400 mg moxifloxacin is accompanied by good penetration through healthy meninges within 2-6 h post-dose and reached adequately high levels in human CSF exerting satisfactory bactericidal activity against penicillin-resistant S. pneumoniae. These results render novel perspectives for a role of moxifloxacin in CNS infections.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinolinas
/
Compostos Aza
/
Líquido Cefalorraquidiano
/
Antibacterianos
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article